Endologix, Inc. (ELGX) Misses Q4 EPS by 1c; Guides FY12 EPS, Revs

Endologix, Inc. (NASDAQ: ELGX) reported Q4 EPS of ($0.06), $0.01 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $23.4 million versus the consensus estimate of $23.67 million.

Endologix, Inc. sees FY2012 EPS of $-0.12-$-0.18, versus the consensus of $-0.07. Endologix, Inc. sees FY2012 revenue of $102-$107 million, versus the consensus of $106.3 million.

For earnings history and earnings-related data on Endologix, Inc. (ELGX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance